Wall Street learned this week that Bristol Myers is expanding its heart drug business with a whopping $13 billion purchase of MyoKardia. The company announced on Monday that it would buy the company for about $13 billion in cash to bolster its porfolio of heart disease treatments. Shares of MyoKardia jumped 57.8% to $220.31 on … Continue reading “Bristol Myers to Acquire MyoKardia for $13 Billion”
